Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and ...

The market dynamics for Epstein-Barr virus (EBV) are evolving, driven by the high prevalence of infection worldwide, the growing recognition of EBV-associated malignancies and other complications, and ...

The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support ...

Sacramento-area resident Lisa Ferrero, was only given 5 years to live before she participated in a clinical trial exploring ...

OnOctober 9, 2026, Yunteng Xinyao (1952.HK) announced the appointment of Dr. Lakshmi Srinivasan as Senior Vice President and ...

New office and laboratory at CIC Philadelphia will support US biopharma companies, CDMOs, and research institutions ...

The potentially registrational Phase 2 study will evaluate CLN-049 in patients with relapsed or refractory AML who have received up to two prior lines of therapy. Following a dose-optimization phase ...

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Vir Biotechnology, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the ...